ASH 2018 | Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse
Thanks for your feedback, this will help us improve our content for you!
Talha Munir, MBBS, of the Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the importance of combining novel agents to achieve deep remissions in relapsed/refractory chronic lymphocytic leukemia (CLL). Referencing the CLARITY study (ISCRTN13751862) of ibrutinib and venetoclax, Dr Munir highlights how the deep remissions produced may allow treatment cessation (with close monitoring). The benefits of time-limited therapies such as this, rather than waiting until the patient is refractory to the therapy, mean that if there is a relapse, the same drugs may still be used. Finally, Dr Munir gives his perspective on the future of CLL treatment. This interview was held at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up